Circulating tumor cells

A reliable biomarker for prostate cancer treatment assessment?

Chiara Ciccarese, Rodolfo Montironi, Michelangelo Fiorentino, Guido Martignoni, Matteo Brunelli, Roberto Iacovelli, Antonio Lopez-Beltranf, Liang Cheng, Marina Scarpelli, Holger Moch, Giampaolo Tortora, Francesco Massari

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Background: Prostate cancer is a common malignancy with highly molecular heterogeneity responsible for a wide spectrum of clinical behavior. To date, several treatment options are available, whose selection is currently based mainly on clinical criteria. Given the weakness of conventional imaging and PSA assay, the identification of a prognostic and predictive biomarker for choosing the appropriate treatment and monitoring its efficacy is a very topical issue in prostate cancer management. Circulating tumor cells (CTCs) have substantial promise for early tumor diagnosis, disease recurrence and metastatic spread monitoring as well as for biological tumor characterization, thus representing a reliable translational real-Time biomarkers of prostate cancer. Conclusion: This paper summarized the main data available about CTCs detection, their prognostic value, and their potential predictive role for metastatic prostate cancer patients management.

Original languageEnglish (US)
Pages (from-to)692-699
Number of pages8
JournalCurrent Drug Metabolism
Volume18
Issue number8
DOIs
StatePublished - Jan 1 2017

Fingerprint

Circulating Neoplastic Cells
Oncology
Biomarkers
Tumors
Prostatic Neoplasms
Cells
Neoplasms
Monitoring
Therapeutics
Early Diagnosis
Assays
Imaging techniques
Recurrence

Keywords

  • Biomarker
  • Circulating tumor cells
  • CTCs
  • Malignancy
  • MCRPC
  • Prostate cancer

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry

Cite this

Ciccarese, C., Montironi, R., Fiorentino, M., Martignoni, G., Brunelli, M., Iacovelli, R., ... Massari, F. (2017). Circulating tumor cells: A reliable biomarker for prostate cancer treatment assessment? Current Drug Metabolism, 18(8), 692-699. https://doi.org/10.2174/1389200218666170518163549

Circulating tumor cells : A reliable biomarker for prostate cancer treatment assessment? / Ciccarese, Chiara; Montironi, Rodolfo; Fiorentino, Michelangelo; Martignoni, Guido; Brunelli, Matteo; Iacovelli, Roberto; Lopez-Beltranf, Antonio; Cheng, Liang; Scarpelli, Marina; Moch, Holger; Tortora, Giampaolo; Massari, Francesco.

In: Current Drug Metabolism, Vol. 18, No. 8, 01.01.2017, p. 692-699.

Research output: Contribution to journalReview article

Ciccarese, C, Montironi, R, Fiorentino, M, Martignoni, G, Brunelli, M, Iacovelli, R, Lopez-Beltranf, A, Cheng, L, Scarpelli, M, Moch, H, Tortora, G & Massari, F 2017, 'Circulating tumor cells: A reliable biomarker for prostate cancer treatment assessment?', Current Drug Metabolism, vol. 18, no. 8, pp. 692-699. https://doi.org/10.2174/1389200218666170518163549
Ciccarese C, Montironi R, Fiorentino M, Martignoni G, Brunelli M, Iacovelli R et al. Circulating tumor cells: A reliable biomarker for prostate cancer treatment assessment? Current Drug Metabolism. 2017 Jan 1;18(8):692-699. https://doi.org/10.2174/1389200218666170518163549
Ciccarese, Chiara ; Montironi, Rodolfo ; Fiorentino, Michelangelo ; Martignoni, Guido ; Brunelli, Matteo ; Iacovelli, Roberto ; Lopez-Beltranf, Antonio ; Cheng, Liang ; Scarpelli, Marina ; Moch, Holger ; Tortora, Giampaolo ; Massari, Francesco. / Circulating tumor cells : A reliable biomarker for prostate cancer treatment assessment?. In: Current Drug Metabolism. 2017 ; Vol. 18, No. 8. pp. 692-699.
@article{53397e123d5e409abe7bd25f79eacc5e,
title = "Circulating tumor cells: A reliable biomarker for prostate cancer treatment assessment?",
abstract = "Background: Prostate cancer is a common malignancy with highly molecular heterogeneity responsible for a wide spectrum of clinical behavior. To date, several treatment options are available, whose selection is currently based mainly on clinical criteria. Given the weakness of conventional imaging and PSA assay, the identification of a prognostic and predictive biomarker for choosing the appropriate treatment and monitoring its efficacy is a very topical issue in prostate cancer management. Circulating tumor cells (CTCs) have substantial promise for early tumor diagnosis, disease recurrence and metastatic spread monitoring as well as for biological tumor characterization, thus representing a reliable translational real-Time biomarkers of prostate cancer. Conclusion: This paper summarized the main data available about CTCs detection, their prognostic value, and their potential predictive role for metastatic prostate cancer patients management.",
keywords = "Biomarker, Circulating tumor cells, CTCs, Malignancy, MCRPC, Prostate cancer",
author = "Chiara Ciccarese and Rodolfo Montironi and Michelangelo Fiorentino and Guido Martignoni and Matteo Brunelli and Roberto Iacovelli and Antonio Lopez-Beltranf and Liang Cheng and Marina Scarpelli and Holger Moch and Giampaolo Tortora and Francesco Massari",
year = "2017",
month = "1",
day = "1",
doi = "10.2174/1389200218666170518163549",
language = "English (US)",
volume = "18",
pages = "692--699",
journal = "Current Drug Metabolism",
issn = "1389-2002",
publisher = "Bentham Science Publishers B.V.",
number = "8",

}

TY - JOUR

T1 - Circulating tumor cells

T2 - A reliable biomarker for prostate cancer treatment assessment?

AU - Ciccarese, Chiara

AU - Montironi, Rodolfo

AU - Fiorentino, Michelangelo

AU - Martignoni, Guido

AU - Brunelli, Matteo

AU - Iacovelli, Roberto

AU - Lopez-Beltranf, Antonio

AU - Cheng, Liang

AU - Scarpelli, Marina

AU - Moch, Holger

AU - Tortora, Giampaolo

AU - Massari, Francesco

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: Prostate cancer is a common malignancy with highly molecular heterogeneity responsible for a wide spectrum of clinical behavior. To date, several treatment options are available, whose selection is currently based mainly on clinical criteria. Given the weakness of conventional imaging and PSA assay, the identification of a prognostic and predictive biomarker for choosing the appropriate treatment and monitoring its efficacy is a very topical issue in prostate cancer management. Circulating tumor cells (CTCs) have substantial promise for early tumor diagnosis, disease recurrence and metastatic spread monitoring as well as for biological tumor characterization, thus representing a reliable translational real-Time biomarkers of prostate cancer. Conclusion: This paper summarized the main data available about CTCs detection, their prognostic value, and their potential predictive role for metastatic prostate cancer patients management.

AB - Background: Prostate cancer is a common malignancy with highly molecular heterogeneity responsible for a wide spectrum of clinical behavior. To date, several treatment options are available, whose selection is currently based mainly on clinical criteria. Given the weakness of conventional imaging and PSA assay, the identification of a prognostic and predictive biomarker for choosing the appropriate treatment and monitoring its efficacy is a very topical issue in prostate cancer management. Circulating tumor cells (CTCs) have substantial promise for early tumor diagnosis, disease recurrence and metastatic spread monitoring as well as for biological tumor characterization, thus representing a reliable translational real-Time biomarkers of prostate cancer. Conclusion: This paper summarized the main data available about CTCs detection, their prognostic value, and their potential predictive role for metastatic prostate cancer patients management.

KW - Biomarker

KW - Circulating tumor cells

KW - CTCs

KW - Malignancy

KW - MCRPC

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85038638114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038638114&partnerID=8YFLogxK

U2 - 10.2174/1389200218666170518163549

DO - 10.2174/1389200218666170518163549

M3 - Review article

VL - 18

SP - 692

EP - 699

JO - Current Drug Metabolism

JF - Current Drug Metabolism

SN - 1389-2002

IS - 8

ER -